HERTHENA-Lung01: Patritumab Deruxtecan in Subjects With Metastatic or Locally Advanced EGFR-mutated Non-Small Cell Lung Cancer
Active, not recruiting · Phase 2 · NCT04619004
Conditions: Non-Small Cell Lung Cancer Metastatic, Non-Small Cell Lung Cancer With Mutation in Epidermal Growth Factor Receptor
At a glance
- Research payments reported, 2025
- $483,464
- U.S. investigators named
- 15
- Sites paid
- 15
- Planned or actual enrollment
- 277
About the trial
- Sponsor
- Daiichi Sankyo (with Daiichi Sankyo Co., Ltd., Merck Sharp & Dohme LLC)
- Tested
- Patritumab Deruxtecan (Fixed dose) (drug), Patritumab Deruxtecan (Up-Titration) (drug)
- Dates
- Started 2021-02-02; completion 2027-01-04
- Results posted
- Yes
This study is designed to evaluate the antitumor activity of patritumab deruxtecan in participants with metastatic or locally advanced NSCLC with an activating EGFR mutation (exon 19 deletion or L858R) who have received and progressed on or after at least 1 EGFR TKI and 1 platinum-based chemotherapy-containing regimen.
From ClinicalTrials.gov, last updated 2026-11-02. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Daiichi Sankyo Inc. reported $483,464 in research payments for this study in 2025 (59 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Kathryn A. Gold, MD Medical Oncology · La Jolla, CA
- Misako Nagasaka, MD Hematology & Oncology · Orange, CA
- Jorge J. Nieva, M.D. Hematology & Oncology · Los Angeles, CA
- Karen L. Reckamp, MD Medical Oncology · Duarte, CA
- Conor E. Steuer, MD Hematology & Oncology · Atlanta, GA
- Pasi Antero Janne, MD PHD Medical Oncology · Boston, MA
- Zofia Piotrowska, MD Medical Oncology · Boston, MA
- Shirish M. Gadgeel, MD Medical Oncology · Detroit, MI
- Jorge E. Gomez, MD Medical Oncology · New York, NY
- Helena Yu, MD Internal Medicine · New York, NY
- Balazs Halmos, MD Hematology & Oncology · Cleveland, OH
- Rachel E. Sanborn, MD Medical Oncology · Portland, OR
- Ryan D. Gentzler, M.D. Medical Oncology · Charlottesville, VA
- Alexander I. Spira, M.D. Medical Oncology · Fairfax, VA
- Christina S. Baik, M.D. Medical Oncology · Seattle, WA
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Dana-Farber Cancer Institute $184,511
- Uci Health-Orange, CA $72,988
- The Regents of the University of California $39,507
- Virginia Cancer Specialists Fairfax $35,408
- Emory University Hospital, GA $34,370
- Cedars-Sinai Medical Center, CA $25,776
- Mount Sinai Hospital, NY $19,343
- University Southern California Keck School of Medicine $17,760
- University of Virginia Medical Center, VA $16,170
- Henry Ford Health Hospital, MI $12,507
- David H Koch Center for Cancer Care at Memorial Sloan Kettering Cancer Center $10,183
- Providence Portland Medical Center, OR $7,647
- Biomedical Research Alliance of New York LLC $5,184
- University of Washington Medical Ctr, WA $1,499
- Regional Cancer Care Associates $611
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.